#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hereditary spastic paraplegia Wolfram syndrome Arteriovenous malformation Endocrine ophthalmopathy Ewing's sarcoma Uveitis Thermal burn Anal squamous cell carcinoma Carcinoid syndrome Dementia Alzheimer's type Diffuse large B-cell lymphoma recurrent Thalassaemia Meningitis meningococcal Waldenstrom's macroglobulinaemia Mitochondrial myopathy More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis III Alveolar rhabdomyosarcoma – Life with Disease Hereditary ataxia – Diagnostics Fragile X syndrome – Life with Disease Lymphatic malformation – Diagnostics Haemophilia A with anti factor VIII – Trials in Disease Myelodysplastic syndrome Hereditary optic atrophy – Life with Disease Mast cell activation syndrome – Treatment Alternating hemiplegia of childhood – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dextran 70 Donepezil Bupropion Hydrochloride Anthoxanthum Odoratum Concizumab Secale Cereale AZD0516 Cannabis Sativa Flower Macitentan TETRODOTOXIN Cefotaxime Sodium Tx200-Tr101 Leuprorelin Deoxyribonucleic Acid NALDEMEDINE Lifileucel MALIC ACID Acetic Acid, Glacial SIPAVIBART Amlitelimab More therapies…

    Learn about Your Condition

    Peripheral artery restenosis Ocular myasthenia Hodgkin's disease refractory Eyelid ptosis Myocarditis Spina bifida Methylmalonic acidaemia Inner ear disorder Meniscus operation Mumps Catatonia Haemorrhage prophylaxis Small intestine leiomyosarcoma Naevoid melanoma Gastrointestinal carcinoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Alpha-1 antitrypsin deficiency

  • A study comparing under-the-skin and into-the-vein alpha1-proteinase inhibitor treatment in patients with alpha1-antitrypsin deficiency

    Recruiting

    3 1 1
    Investigated Diseases:
    • Alpha-1 antitrypsin deficiency
    Investigated Drugs:
    • Human Alpha1-Proteinase Inhibitor
    Denmark France Germany Ireland The Netherlands Poland +3

  • Study on the Safety of Self-Infusion Therapy with Human Alpha1-Proteinase Inhibitor for Patients with Severe Alpha-1 Antitrypsin Deficiency

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Human Alpha1-Proteinase Inhibitor
    Germany

  • Study on the Safety and Effectiveness of BEAM-302 with MR0005 and GR0015 for Adults with Alpha-1 Antitrypsin Deficiency-Related Lung or Liver Disease

    Recruiting

    2 1 1
    Investigated Diseases:
    • Alpha-1 antitrypsin deficiency
    Investigated Drugs:
    • Gr0015
    • Mr0005
    Ireland The Netherlands

  • Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency Liver Disease and Mild Fibrosis

    Recruiting

    3 1 1
    Investigated Diseases:
    • Alpha-1 antitrypsin deficiency
    Investigated Drugs:
    • Fazirsiran
    • Saline
    Austria Belgium France Germany Ireland Italy +4

  • Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease and Fibrosis

    Recruiting

    3 1 1
    Investigated Drugs:
    • Fazirsiran
    • Saline
    Austria Belgium Czechia Denmark France Germany +7

  • Study on Long-Term Safety of Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease

    Recruiting

    3 1 1
    Investigated Drugs:
    • Fazirsiran
    Austria Germany Portugal
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!